Major depressive disorder (MDD) is the leading cause of disability worldwide and is
associated with high rates of suicide and medical comorbidities. Current antidepressant …

Antidepressant medications are the most common treatment for major depression and
related disorders. Pharmacogenetic studies have demonstrated that response to these …

There has been a limited number of systematic reviews conducted to summarize the
overview of the relationship between DNA methylation and depression, and to critically …

As one of the most common psychiatric disorders, depression has been a major public
health problem. Growing evidence suggests that epigenetic modification is essential in …

Major depressive disorder (MDD) is primarily treated with antidepressants, yet many patients
fail to respond adequately, and identifying antidepressant response biomarkers is thus of …

Background Growing evidence suggests that epigenetic modification is vital in biological
processes of depression. Findings from studies exploring the associations between DNA …

Pharmacotherapy is the most common treatment for schizophrenia (SCZ), bipolar disorder
(BD), and major depressive disorder (MDD). Pharmacogenetic studies have achieved …

Depression is one of the most common psychiatric disorders affecting public health. Studies
over the past years suggest that the methylations of some specific genes such as BDNF …

Depressive disorder is a complex, heterogeneous disease that affects approximately 280
million people worldwide. Environmental, genetic, and neurobiological factors contribute to …

Background Evidence has supported a role of DNA methylation in the pathophysiology of
mood disorders. The purpose of the current study is to examine 5-methylcytosine (5-mc) and …